| Primary | Percent Change in Time of Circulating Estradiol SPE in Each Arm | LS means of percent change | | Posted | | Least Squares Mean | 95% Confidence Interval | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-89(-95 to -83)
- OG001-85(-98 to -73)
- OG002-60(-78 to -42)
|
|
| |
| Secondary | Percent Change in Time of Circulating Estradiol LLE in Each Arm | LS means of percent change | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Estrone SPE | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Estrone LLE | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Total Estrone | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Estrone Sulfate | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Androstenedione | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Testosterone | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Testosterone CLIA | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating SHBG | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Total Cholesterol | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating HDL Cholesterol | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating LDL Cholesterol | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Triglycerides | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Insulin | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Serum Glucose | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of HOMA IR | Insulin Resistance Index (HOMA-IR) measures insulin resistance, calculated by fasting insulin (mU/L) multiplied by fasting glucose (mmol/L), and divided by a constant (22.5). A higher score indicates higher insulin resistance. | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Adiponectin | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Percent Change of Circulating Leptin | [(Final levels-baseline levels)/baseline levels]*100 | | Posted | | Median | Inter-Quartile Range | percent change | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Exemestane Blood Concentration at Surgery | | | Posted | | Median | Inter-Quartile Range | pmol/L | | at surgery | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | 17-OH Exemestane Blood Concentration at Surgery | | | Posted | | Median | Inter-Quartile Range | pmol/L | | at surgery | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Change of ER Expression (Cancer Tissue), Central Review | Surgery level-biopsy level. | | Posted | | Median | Inter-Quartile Range | Abs change of % of positive tumor cells | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Change of PgR Expression (Cancer Tissue), Central Review | Surgery level-biopsy level. | | Posted | | Median | Inter-Quartile Range | Abs change of % of positive tumor cells | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Change of Ki67% Expression (Cancer Tissue), Central Review | Surgery level-biopsy level. | | Posted | | Median | Inter-Quartile Range | Abs change of % of positive tumor cells | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Change of Ki67% Expression (Adjacent Non Cancer Tissue), Central Review | Surgery level-biopsy level. | | Posted | | Median | Inter-Quartile Range | Absolute change of % of positive cells | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Estradiol Tissue Concentration at Surgery | Final biomarker concentration | | Posted | | Median | Inter-Quartile Range | fmol/g wet weight | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Estrone Tissue Concentration at Surgery | Final biomarker concentration | | Posted | | Median | Inter-Quartile Range | fmol/g wet weight | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Androstenedione Tissue Concentration at Surgery | Final biomarker concentration. | | Posted | | Median | Inter-Quartile Range | fmol/g wet weight | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Testosterone Tissue Concentration at Surgery | Final biomarker concentration | | Posted | | Median | Inter-Quartile Range | fmol/g wet weight | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Exemestane Tissue Concentration at Surgery | | | Posted | | Median | Inter-Quartile Range | fmol/g wet weight | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | 17 OH Exemestane Tissue Concentration at Surgery | | | Posted | | Median | Inter-Quartile Range | fmol/g wet weight | | 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Secondary | Change in MenQoL Questionnaire Score | MenQOL questionnaire assessed how bothered participants were with 31 symptoms. It contains domains: vasomotor (items 1-3); psychosocial (items 4-10); physical (items 11-26); sexual (items 27-29); in addition to nausea and indigestion. 31 individual symptoms are rated on a scale of 0 (not at all bothered) to 6 (extremely bothered). Total possible score ranged from 0 to 186. MenQOL summary score was calculated as mean of four domain scores (Physical function, Psychosocial function, Sexual function and Vasomotor function) ranging from 1 to 8, with higher scores indicating worse quality of life. Final score-baseline score | | Posted | | Median | Standard Deviation | score on a scale | | baseline and 4-6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Exemestane 25 mg QD | 1 tablet of exemestane 25 mg a day for up to 6 weeks | | OG001 | Exemestane 25 mg TIW | 1 tablet of exemestane 25 mg a day (on days 1, 3, 5) and 1 tablet of placebo on days 2, 4, 6, 7 for up to 6 weeks | | OG002 | Exemestane 25 mg QW | 1 tablet of exemestane 25 mg a day (on day 1) and 1 tablet of placebo on days 2 to 7 for up to 6 weeks |
| |
| Other Pre-specified | Proteomic Analysis | The Proteomic Analysis was not performed. | | Not Posted | | | | | | 4-6 weeks | | Participants | | | | |